A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eligible age
18+ yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Where it's recruiting
Jacksonville · Miami · Sarasota
Atlanta
Chicago
Boston
Rochester
Omaha
Ithaca · Lake Success · New York
Durham
Columbus
Philadelphia
Nashville
Houston
Source: ClinicalTrials.gov · NCT06876649 · last updated 2026-03-02